The Latest Breaking News from JNJ

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), has announced results from the 

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

Johnson & Johnson (NYSE: JNJ) and the three U.S.

Rising inflation and the Fed’s signal that it will raise interest rates multiple times this year fostered high market volatility last month. And although the major market indexes rose for the third consecutive trading session yesterday, many analysts expect the market to remain volatile this year. Given this backdrop, we…

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Someone with a lot of money to spend has taken a bullish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Johnson & Johnson expects at least $3 billion in sales of its Covid vaccine this year, and JNJ stock ticked higher Tuesday.

Johnson & Johnson (NYSE: JNJ) 

  Johnson & Johnson (NYSE:JNJ) reported its Q4 earnings results on Tuesday, January 25, 2022 at 06:30 AM. Here's what investors need to know about the announcement.